 Inhibitors of farnesyl protein transferase |
| OF THE INVENTION Definition of Terms Listed below are definitions of various terms used to ... |
|
| Cerulenin compounds for fatty acid synthesis inhibition |
| OF THE INVENTION I. FAS The protein FAS (also referred to herein as OA-519) is highly correlated ... |
|
| Inhibitors of prenyl-protein transferases |
| OF THE INVENTION The compounds of this invention inhibit the prenylation of proteins by the ... |
|
| Genetic alterations associated with cancer |
| The present invention provides compositions and methods for detecting genetic alterations ... |
|
| Methods and reagents to detect and characterize norwalk and related viruses |
| OF THE INVENTION It is readily apparent to one skilled in the art that various substitutions and ... |
|
| Human medical treatment by aerosol inhalation of immunoglobulin A |
| OF THE PREFERRED EMBODIMENTS The following description of the preferred embodiment(s) is merely ... |
|
| Cell culture process and medium for the growth of adherent animal cells |
| We have now found that it is possible to eliminate cell aggregation in the culture of CHO-derived ... |
|
| Reactor heater |
| Having thus described our invention and certain embodiments thereof, we claim: 1. In combination, a ... |
|
| Electrical leads for a fluid heaters |
| The present invention sets forth a method and a structure for connecting electrical power to the ... |
|
|
Vaccine for immunizing cats against toxoplasma oocyst shedding
| Details |
Inventors: Frenkel, Jacob K.; Pfefferkorn, Elmer R.;
Assignee: The University of Kansas (Lawrence, KS); Darmouth College (Hanover, NH)
Primary Examiner: Moskowitz; Margaret
Assistant Examiner: Mohamed; Abdel A.
Attorney, Agent or Firm: Hovey, Williams, Timmons & Collins
A new mutant strain vaccine, and a corresponding method of immunization, against Toxoplasma in cats is provided which makes use of a reproductively deficient strain of T.gondii, designated T-263. Bradyzoites in tissue cysts from laboratory animals infected with the mutant were fed to cats, which developed immunity against subsequent T.gondii challenge without concomitant shedding of infectious oocysts. The new vaccine eliminates the need for chemoprophylaxis subsequent to primary infection. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A method of immunizing cats against Toxoplasmosis without concomitant oocyst shedding by said cats, said method consisting essentially of administering to said cats an effective amount of a mutant of T.
gondii, said mutant being designated as T-263 mutant and having ATCC Accession No.
40615.
2.
The method of claim 1, said mutant being administered orally to said cats.
3.
A vaccine for immunizing cats against Toxoplasmosis without concomitant oocyst shedding by said cats, said vaccine comprising a mutant of T.
gondii, said mutant being designed as T263 and having ATCC Accession No.
40615.
Description:
BACKGROUND OF THE INVENTION 1.
Field of the Invention The present invention is broadly concerned with a method of immunizing cats against Toxoplasmosis wherein use is made of a live, reproductively deficient mutant of Toxoplasma gondii.
More particularly, it is concerned with such a method, and the associated vaccine, wherein the mutant is designated T-263 and has ATCC Accession No.
40615.
2.
Description of the Prior Art Toxoplasmosis is a parasitic disease, and research has indicated that the parasite has a complicated life cycle with the infection spreading to many animals.
Oocysts (egg spores) are shed in the feces of domestic cats and certain types of wild cats.
Oocysts are then spread by contact with the feces.
Flies and cockroaches, which eat feces, can serve as transport agents, contaminating animals which do not directly encounter the cat feces.
Mice and birds can be infected either from transport agents, or through direct contact and can then spread the infection to animals which prey on them.
Humans can be infected by eating raw or rare meats, or by direct contact with infected cat feces, or contaminated soil.
Toxoplasma infections are quite prevalent, with one-quarter to one-half of the adults in the United States and elsewhere asymptomatically infected.
While the presence of Toxoplasma infections has long been known, little was discovered about the transmission of Toxoplasma until the late 1930's and 1940's when Toxoplasmosis was found in newborn babies in the U
|
| Related patents |
|
|
Attenuated viruses
We claim: 1. An attenuated poliovirus in which there is a reversal of a base pairing in the part, or in a part corresponding to the part, of the 5' non-coding region of ...
|
|
|
Chimeric nucleic acids and proteins for inhibiting HIV-1 expression
OF THE INVENTION A fusion protein according to the invention includes NS1 and Rev proteins or fragments or derivatives of the NS1 and Rev proteins. The NS1protein, ...
|
|
|
Citrus peel extract as 3-hydroxy-3-methylglutaryl CoA(HMG-CoA) reductase inhibitor
OF THE INVENTION The method of the present invention for inhibiting the activity of HMG-CoA in mammal comprises administering citrus peel extract thereto. The citrus ...
|
|
|
Heat shock-like protein
What is claimed is: 1. An isolated and purified polynucleotide sequence which encodes the heat shock-like protein (HSPRO) of SEQ ID NO:1. 2. A hybridization probe ...
|
|
|
Antiviral peptides
OF THE INVENTION While the specification concludes with claims particularly pointing out and specifically claiming the subject matter regarded as forming the present ...
|
|
|
Immunoglobulins devoid of light chains
We claim: 1. An immunoglobulin comprising two heavy polypeptide chains, each heavy chain consisting of a complete antigen binding site, said immunoglobulin containing a ...
|
|
|
Buffered serum substitute for blood oxygen analyzer
What is claimed is: 1. A buffered serum substitute for receiving a blood sample, said serum substitute comprising a 0.9% saline solution containing 5 millimolar of ...
|
|
|
Analytical method for determining volatiles, solids and solvent extractables
What is claimed is: 1. A method for determining amounts of volatiles, solids, and solvent extractable solid in a sample containing the same comprising placing the sample ...
|
|
|
Methods for determining the invasiveness of a bladder tumor
Briefly stated, the present invention provides, in one aspect, methods for determining the invasiveness of a bladder tumor. In one embodiment, the method comprises the ...
|
|
|
Compounds for inhibition of protein methylation
In general, the invention features certain novel compounds which inhibit methylation of proteins having a carboxyl-terminal --CAAX motif (C=cysteine, A=aliphatic amino ...
|
|
|
Drugs 
